Biotech deals involving assets developed in China are surging, a Jefferies report shows. | Biotech deals involving assets ...

Sun Pharma has introduced LEQSELVITM (deuruxolitinib) 8 mg tablets in the US for severe alopecia areata after settling a patent dispute with Incyte. Approved by the FDA and backed by strong clinical ...

U.S. inspectors have found new breakdowns at a Sun Pharmaceuticals plant in India that produces medications for U.S. customers, ProPublica reported July 16. The FDA found the factory failed to ...

The latest inspection comes 2 1/2 years after the agency allowed Sun Pharma to keep shipping some drugs to Americans even ...

Although anti-PD-1 therapy, alone or in combination with an anti-CTLA-4 agent, has become the first-line standard of care for ...

Sun Pharma shares surged after a settlement with Incyte over Leqselvi, a drug for severe hair loss. The agreement includes a ...

Indian drugmaker Sun Pharmaceutical Industries together with its subsidiaries announced that further to its intimation dated ...

India VIX, the fear gauge, eased 3 percent which suggests that there are little-to-no signs of panic-driven exits.

Sun recieved approval from the US Food and Drug Administration for Leqselvi in July 2024. Soon after the regulator’s approval ...

Oil held a drop — after slumping by more than 2% on Monday — as Trump’s latest plan to pressure Russia refrained from ...

In a regulatory filing on Monday, Sun Pharma announced that it has reached a settlement and licensing agreement with Incyte ...

The Indian equity indices, the Sensex and the Nifty, are expected to open on a flat-to-higher note on Tuesday, following ...